-

BioTek reMEDys Calls for Heightened Communication Around Health Literacy Month

NEW CASTLE, Del.--(BUSINESS WIRE)--With October being Health Literacy Month, BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is calling for greater emphasis on communication to improve optimal health literacy.

For more than 20 years, October has been recognized as Health Literacy Month. To participate this year, BioTek is proactively promoting the observance among patients, patient loved ones, colleagues, pharmacists, hospitals, health centers, and other groups working together to integrate and expand the mission of health literacy.

BioTek reMEDys is urging its clinical and patient constituents and the population at large to become more literate and get involved to establish deeper understanding of specific conditions and associated treatments and medications.

“While it’s something we focus on year round, during Health Literacy Month we work to further promote our efforts to encourage patients and patient families to put health literacy awareness into action,” said BioTek reMEDys’ CEO and founder Chaitanya Gadde. “At BioTek, we are fully committed to patients first. Part of that involves communicating consistently with health providers, pharmacists, and family so that solid bridges of awareness can be established between the health system and the people who need care. Greater health literacy helps us overcome barriers and challenges. By collectively working to improve health literacy, we can also establish a more equitable scenario where patients can access appropriate and high-quality care.”

As part of the effort to expand upon health literacy, BioTek reMEDys’ team of Immunoglobulin National Society (IgNS) certified pharmacists will be attending this week’s IgNS 2023 conference in Denver for the latest clinical education, practice advancements and best practices to share with patients and colleagues.

BioTek reMEDys is a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases. Through supply chain management, innovative technology and trained specialty pharmacists, BioTek reMEDys is able to deliver superior service at a lower cost. The company bridges the gap between managed care, physicians and patients by facilitating the authorization, procurement and administration of specialty medications and infusions. BioTek reMEDys provides high-touch therapies, biologics and pharmaceuticals to support treatment for patients with rare diseases and chronic conditions, ensuring the highest quality of care. For information visit www.biotekrx.com.

Contacts

Paul Williams
paul@medialinecommunications.com
310/569-0023

BioTek reMEDys


Release Versions

Contacts

Paul Williams
paul@medialinecommunications.com
310/569-0023

Social Media Profiles
More News From BioTek reMEDys

BioTek reMEDys Encourages Education and Awareness for Autoinflammatory Conditions

NEW CASTLE, Del.--(BUSINESS WIRE)--BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for year-round enhanced education and awareness of these rare diseases and conditions. Autoinflammatory diseases refer to problems with the innate immune system’s reactions. Immune cells target the body’s own healthy tissues by mistake, signaling the body to attack them. This can cause intense episodes of inf...

BioTek reMEDys Celebrates the Work of Collaborating Healthcare Professionals During National Interprofessional Healthcare Month

NEW CASTLE, Del.--(BUSINESS WIRE)--In recognition of National Interprofessional Healthcare Month, BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for awareness of safe medication use for patients with rare diseases and conditions, while celebrating the critical contributions and collaborative spirit of healthcare professionals nationwide, applauding the efforts of those who impact the patie...

BioTek reMEDys Names Neal Fitzpatrick Chief Strategy Officer

NEW CASTLE, Del.--(BUSINESS WIRE)--BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, has named Neal C. Fitzpatrick as its Chief Strategy Officer. Fitzpatrick recently served as Chief Commercial Officer at a biotech company, charged with leading the organization through a period of high growth. Before this, he served as Vice-President of Sales at ADMA Biologics, where he repositioned an essential product from hos...
Back to Newsroom